Rotop expands production of radiopharmaceuticals

Rotop Pharmaka GmbH is investing a double-digit million euro amount to expand its production and development capacities for radiopharmaceuticals at the Dresden-Rossendorf site. The investment package corresponds to approximately twice the annual turnover and marks the beginning of the next growth phase, the company announced. Exact amounts were not disclosed. Rotop plans to celebrate its 25th anniversary on Friday afternoon.

Highly automated production for radiopharmaceuticals

There are plans to build two highly automated factories for diagnostic and therapeutic radiopharmaceuticals, which are due to start operating in stages from 2028. Radiopharmaceuticals are radioactively labeled drugs that are used to diagnose or treat diseases.

"Here in Rossendorf, we are investing in the largest radiopharmaceutical project currently underway in Germany." It is also the largest investment program in the company's history, explained Managing Director Jens Junker. This magnitude could not be achieved alone. Without strong partners from private capital, the public sector, associations and the expertise of the workforce, such a step would not be possible. Rotop currently employs 230 people from 15 countries.

Radiopharmaceuticals for one million patients per year

According to the company, around one million patients per year can be treated with the radiopharmaceuticals produced in Dresden. The radiopharmaceuticals are used for diagnostic applications in the areas of functional diagnostics and cancer diagnostics and are supplied to customers in Germany, Europe and the United States. The increasing demand is now leading to space bottlenecks at the site, it said.

Michael Kretschmer (CDU), Minister-President of Saxony, commented on the anniversary by saying that Rotop has stood for cutting-edge research, entrepreneurial courage and ground-breaking innovation in Saxony for 25 years. "The progress in nuclear medicine shows how much scientific excellence is advancing our state and improving lives in concrete terms."